https://orcid.org/0000-0001-5459-4973
References
- de Oliveira LH, Camacho LA, Coutinho ES, et al. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11(12):e0166736.
- Cohen O, Knoll M, O’Brien K, et al. Pneumococcal conjugate vaccine (PCV) product assessment. 2017. Available from: https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf.
- World Health Organization. Meeting of the strategic advisory group of experts (SAGE) on immunization, October 2017 – conclusions and recommendations. Weekly Epidemiological Rec. 2017;92:729–748.
- World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. Weekly Epidemiological Record. 2019;94(8):85-104.
- Castaneda-Orjuela C, Alvis-Guzman N, Velandia-Gonzalez M, et al. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine. 2012;30(11):1936–1943.
- Marti SG, Colantonio L, Bardach A, et al. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc. 2013;11(1):21.
- Ordonez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia. Cost Eff Resour Alloc. 2015;13:6.
- Castaneda-Orjuela C, De la Hoz-Restrepo F. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country. Vaccine. 2018;36(38):5766–5773.
- National Institute of Health Colombia. Vigilancia por Laboratorio de aislamientos invasores de Streptococcus pneumoniae Colombia 2006–2018 (SIREVA II). Dirección Redes en Salud Pública. Ministerio de Salud de Colombia. [cited 2021 May 30]. Available from: https://www.ins.gov.co/buscador-eventos/Informacin%20de%20laboratorio/Vigilancia%20por%20laboratorio%20S.%20pneumoniae%202006-2018.pdf.
- Deloria Knoll M, Bennett JC, Garcia Quesada M, et al. Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13: the pneumococcal serotype replacement and distribution estimation (PSERENADE) project. Microorganisms. 2021 Apr 2;9(4):742. PMID: 33918127; PMCID: PMC8066045.
- World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. Weekly Epidemiological Rec. 2019;94(8):85–104.
- Domingues CM, Verani JR, Montenegro Renoiner EI, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2(6):464–471.
- Deceuninck G, De Serres G, Boulianne N, et al. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–2689.
- Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. PLoS One. 2015;10(3):e0120290.
- Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines. 2015;14(3):413–428.